Search
Close this search box.
Search
[custom_company_search_form]
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)
Lithium
43.48
0.23%
Gold
2,665.20
0.06%
Copper
4.35
(1.31%)
Oil
70.25
(1.76%)
Bitcoin
66,557.52
0.75%
FTSE 100
8,253.78
(0.47%)
Nikkei 225
39,910.55
(0.34%)
Dow Jones
42,863.82
(0.87%)
Iron Ore
106.40
(1.11%)
USD/AUD
0.67
(0.05%)
Hang Seng
20,318.79
(3.46%)

Clarity Pharmaceuticals Ltd

CU6

ASX

Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company provides innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

Latest Posts

Line Chart with Gradient
Price
$6.81
-0.09 (-1.3%)
At Close 14/10 (AEST)
Related Companies
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
$NSB
PROTEOMICS INTERNATIONAL LABORATORIES LTD
$PIQ
MAYNE PHARMA GROUP LIMITED
$MYX
CANN GROUP LIMITED
$CAN
TELIX PHARMACEUTICALS LIMITED
$TLX

Latest Posts

clarity-pharmaceuticals-asx-cu6-develops-next-generation-radiopharmaceuticals-for-cancer-treatment-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) develops next-generation radiopharmaceuticals for cancer treatment

Global leader in Targeted Copper Theranostics with significant supply and logistical benefits

September 18, 2024
clarity-pharmaceuticals-asx-cu6-advances-secure-trial-with-strong-preliminary-efficacy-data-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) advances secure trial with strong preliminary efficacy data

Cohort 4 shows positive safety profile and significant PSA reduction in prostate cancer patients

September 12, 2024
clarity-pharmaceuticals-asx-cu6-signs-supply-agreement-with-terrapower-for-ac-225-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) signs supply agreement with TerraPower for ac-225

Agreement to develop best-in-class TAT 225Ac-bisPSMA product with secure supply

July 16, 2024
clarity-pharmaceuticals-asx-cu6-completes-retail-entitlement-offer-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) completes retail entitlement offer

Raises approximately $10.8 million in final stage of capital raising

April 24, 2024
clarity-pharmaceuticals-asx-cu6-announces-equity-raising-to-fund-clinical-programs-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) announces equity raising to fund clinical programs

A$121m raised to strengthen balance sheet and advance clinical portfolio

April 4, 2024
clarity-pharmaceuticals-asx-cu6-completes-placement-and-institutional-entitlement-offer-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) completes placement and institutional entitlement offer

Raises $110 million to advance clinical portfolio and strengthen balance sheet

March 28, 2024
clarity-pharmaceuticals-asx-cu6-raises-a121m-to-fund-clinical-programs-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) raises A$121m to fund clinical programs

Developing next-generation radiopharmaceuticals for cancer treatment

March 26, 2024
clarity-pharmaceuticals-asx-cu6-launches-121-million-equity-raising-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) launches $121 million equity raising

Underwritten equity raising to fund clinical program and product development

March 26, 2024
clarity-pharmaceuticals-asx-cu6-treats-first-participant-in-final-secure-trial-cohort-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) treats first participant in final SECURE trial cohort

Phase I/II SECURE trial progresses to final dose escalation phase with 67Cu-SAR-bisPSMA

March 22, 2024
clarity-pharmaceuticals-asx-cu6-advances-theranostic-prostate-cancer-trial-to-multi-dose-phase-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) advances theranostic prostate cancer trial to multi-dose phase

SECURE trial progresses to cohort 4 with favorable safety profile and promising PSA reductions

March 15, 2024
clarity-pharmaceuticals-asx-cu6-reveals-enhanced-detection-of-prostate-cancer-lesions-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX: $CU6) reveals enhanced detection of prostate cancer lesions

64Cu-SAR-bisPSMA detects lesions as small as 2mm, potentially revolutionizing prostate cancer diagnosis

March 6, 2024
clarity-pharmaceuticals-asxcu6-closes-recruitment-early-for-diagnostic-phase-ii-trial-cu6
Health Care $CU6

Clarity Pharmaceuticals (ASX:CU6) closes recruitment early for diagnostic phase II trial

Phase II trial for 4CU-SARTATE in neuroendocrine tumours concludes with early recruitment closure

December 19, 2023

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) develops next-generation radiopharmaceuticals for cancer treatment

Global leader in Targeted Copper Theranostics with significant supply and logistical benefits

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) advances secure trial with strong preliminary efficacy data

Cohort 4 shows positive safety profile and significant PSA reduction in prostate cancer patients

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) signs supply agreement with TerraPower for ac-225

Agreement to develop best-in-class TAT 225Ac-bisPSMA product with secure supply

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) completes retail entitlement offer

Raises approximately $10.8 million in final stage of capital raising

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) announces equity raising to fund clinical programs

A$121m raised to strengthen balance sheet and advance clinical portfolio

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) completes placement and institutional entitlement offer

Raises $110 million to advance clinical portfolio and strengthen balance sheet

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) raises A$121m to fund clinical programs

Developing next-generation radiopharmaceuticals for cancer treatment

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) launches $121 million equity raising

Underwritten equity raising to fund clinical program and product development

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) treats first participant in final SECURE trial cohort

Phase I/II SECURE trial progresses to final dose escalation phase with 67Cu-SAR-bisPSMA

CU6

$CU6

Clarity Pharmaceuticals (ASX: $CU6) advances theranostic prostate cancer trial to multi-dose phase

SECURE trial progresses to cohort 4 with favorable safety profile and promising PSA reductions

Load More
No More Posts
Related Companies
PRESCIENT THERAPEUTICS LIMITED
$PTX
RACE ONCOLOGY LTD
$RAC
NYRADA INC.
$NYR
RADIOPHARM THERANOSTICS LIMITED
$RAD
CANN GROUP LIMITED
$CAN

ASX News, First
& Fast.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

By clicking Subscribe, you agree to our Terms & Conditions

© 2024 Stock Piper. All rights reserved

© 2024 Stock Piper.
All rights reserved

Blog

Healthcare
Materials
Real Estate
Consumer Staples
Consumer Discretionary Brief
Utilities

Company

About us
Terms of use
Privacy Policy

Support

Request Form
Contact Support
FAQ
Glossary

Socials

Facebook
Twitter
LinkedIn
© 2024 Stock Piper. All rights reserved
Social Media Auto Publish Powered By : XYZScripts.com
Stock Piper AI Index
Subscribe
Join FREE Newsletter

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions